Last reviewed · How we verify

Biocad — Portfolio Competitive Intelligence Brief

Biocad pipeline: 2 marketed, 0 filed, 22 Phase 3, 8 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 22 Phase 3 8 Phase 2 12 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Methotrexat Methotrexat marketed Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4 Oncology
Sodium Enoxaparine Sodium Enoxaparine marketed Low-molecular-weight heparin (LMWH) Factor Xa and Factor IIa (via antithrombin III enhancement) Cardiovascular
Cisplatin (or Carboplatin) Cisplatin (or Carboplatin) phase 3 Platinum-based chemotherapy agent DNA Oncology
BCD-264 BCD-264 phase 3 PD-L1 inhibitor PD-L1 Oncology
BCD-131 (pegdarbepoetin beta) BCD-131 (pegdarbepoetin beta) phase 3 Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR) Hematology/Oncology
BCD-281 BCD-281 phase 3 PD-L1 inhibitor PD-L1 Oncology
BCD-148 BCD-148 phase 3 PD-L1 inhibitor PD-L1 Oncology
anti-TRBV9 monoclonal antibody infusions anti-TRBV9 monoclonal antibody infusions phase 3 monoclonal antibody (T-cell depleting) TRBV9 (T-cell receptor beta variable 9 segment) Immunology / Oncology
BCD-055 BCD-055 phase 3 PD-L1 inhibitor PD-L1 Oncology
BCD-085 Q2W BCD-085 Q2W phase 3 PD-L1 inhibitor PD-L1 Oncology
Adalimumab subcutaneous injection Adalimumab subcutaneous injection phase 3 TNF-α inhibitor (monoclonal antibody) TNF-α (Tumor Necrosis Factor-alpha) Immunology
BCD-201 BCD-201 phase 3 PD-L1 inhibitor PD-L1 Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Celltrion · 3 shared drug classes
  2. GlaxoSmithKline · 3 shared drug classes
  3. Jiangsu HengRui Medicine Co., Ltd. · 3 shared drug classes
  4. Federation Francophone de Cancerologie Digestive · 2 shared drug classes
  5. Bayer · 2 shared drug classes
  6. Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
  7. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 2 shared drug classes
  8. Amgen · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Biocad:

Cite this brief

Drug Landscape (2026). Biocad — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biocad. Accessed 2026-05-13.

Related